Surrozen, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Surrozen, Inc. Surrozen, Inc. (Nasdaq: SRZN) is a clinical-stage biotechnology company that discovers and develops antibody-based therapeutics to selectively modulate the Wnt pathway for tissue repair and regeneration across multiple organs. The company focuses on high-unmet-need indications, particularly in ophthalmology, with lead product candidates including SZN-814, which combines Frizzled 4 (Fzd4) agonism and vascular endothelial growth factor (VEGF) antagonism for diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy; SZN-8143, which adds interleukin-6 modulation to Fzd4 agonism and VEGF antagonism for DME, wet AMD, and uveitic macular edema; SZN-113 for Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4-targeted bispecific antibody for retinal vascular diseases; its pipeline also targets diseases of the lung, intestine, liver, kidney, cochlea, skin, pancreas, and central nervous system using proprietary SWAP and SWEETS platforms. Founded in 2015 and headquartered in South San Francisco, California, Surrozen, Inc. operates primarily in the United States with approximately 41 employees and serves patients through collaborations with pharmaceutical partners. Recent developments include a $175 million oversubscribed private placement financing in March 2025 led by Venrock Healthcare Capital Partners to advance ophthalmology programs like SZN-8141 and SZN-8143 through Phase 1 clinical studies, while discontinuing SZN-043 for severe alcohol-associated hepatitis; an ongoing collaboration and license agreement with Boehringer Ingelheim International GmbH for Fzd4 bispecific antibodies including SZN-413 in retinal diseases, providing upfront payments, up to $587 million in milestones, and royalties; a research collaboration with TCGFB, Inc. on TGF-β antibodies for pulmonary fibrosis; positive Q2 2025 financial results with $39.7 million net income; and progression toward investigational new drug submissions for lead ophthalmology candidates as of Q3 2025.
Company News
Surrozen to Present at Upcoming Healthcare Investor Conferences
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright
Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Head-To-Head Review: Surrozen (NASDAQ:SRZN) & MediWound (NASDAQ:MDWD)
Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?
Tcg Crossover Gp Ii, Llc Acquires 106,658 Shares of Surrozen (NASDAQ:SRZN) Stock
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Tcg Crossover Gp Ii, Llc Purchases 12,374 Shares of Surrozen (NASDAQ:SRZN) Stock
Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Surrozen (NASDAQ:SRZN) & Galmed Pharmaceuticals (NASDAQ:GLMD) Financial Review
Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Purchases 18,052 Shares of Stock
Surrozen (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Acquires 11,893 Shares of Stock
Surrozen (NASDAQ:SRZN) Director Tim Kutzkey Acquires 18,052 Shares